Associated Papers
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African Populations.
Twesigomwe D et al.
Clinical Pharmacology and Therapeutics, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Multidisciplinary Insights into the Structure-Function Relationship of the CYP2B6 Active Site.
Angle ED et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2023
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Analysis of protein missense alterations by combining sequence- and structure-based methods.
Gyulkhandanyan A et al.
Molecular Genetics & Genomic Medicine, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Role of CYP2B6 pharmacogenomics in bupropion-mediated smoking cessation.
Tran AX et al.
Journal of Clinical Pharmacy and Therapeutics, 2019
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Pharmacogenetics of antiretroviral therapy.
Barreiro P et al.
Expert Opinion on Drug Metabolism & Toxicology, 2014
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools.
Radloff R et al.
Human Mutation, 2013
Analysis of pharmacogenetic traits in two distinct South African populations.
Ikediobi O et al.
Human Genomics, 2011
Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection.
Jamshidi Y et al.
The Journal of Antimicrobial Chemotherapy, 2010
Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients.
Gounden V et al.
Aids Research and Therapy, 2010
Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22).
Watanabe T et al.
Pharmacogenetics and Genomics, 2010
Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
Kwara A et al.
Journal of Clinical Pharmacology, 2008
CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.
Wang H et al.
Current Drug Metabolism, 2008
Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7.
Rotger M et al.
Pharmacogenetics and Genomics, 2007
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.
Rotger M et al.
Clinical Pharmacology and Therapeutics, 2007